WOBURN, Mass. — Medicinal Genomics and Courtagen Life Sciences, today announced that former All-Pro NFL offensive lineman, Kyle Turley, will be a featured speaker at CannMed2016. This first annual Personalized Cannabinoid Medicine Conference will be held at The Joseph B. Martin Conference Center at The Harvard School of Medicine April 10-11, 2016. The conference will feature internationally recognized thought leaders, scientists, physicians, and advocates working to advance research into the endocannabinoid system and cannabinoid therapeutics.
Through his Gridiron Cannabis Coalition, Turley advocates for increased research in the use of medical cannabis to treat numerous chronic conditions common to both active and retired athletes. Turley will be joining an influential group of presenters at CannMed 2016, including Dr. Raphael Mechoulam, professor in the Department for Medicinal Chemistry and Natural Products at Hebrew University Hadassah Medical School and School of Pharmacy, Institute for Drug Research. Dr. Mechoulam, a pioneer in the field of cannabis research is often referred to as the “Father of Marijuana Research.” He is credited with isolating THC, the psychoactive component of marijuana, and discovered the endocannabinoid system (ECS), a group of endogenous cannabinoid receptors located in the brain and throughout the central and peripheral nervous systems.
“The sport of American Football is plagued with multiple ailments and diseases currently void of non-addictive treatments or cures,” said Turley. “The Gridiron Cannabis Coalition is determined to forward the movement to allow players and the public the option of an organic treatment for injury and illness through cannabis. We are thrilled to be included in the company of such respected scientists, physicians and advocates at CannMed2016 this spring.”
Turley’s presentation will focus on Chronic Traumatic Encephalopathy (CTE), the neurological condition associated with repetitive brain injury from multiple concussions, and the use of medical cannabis as a viable treatment option.
CannMed2016 will be the first medical cannabis conference to focus on the intersection of clinical application, medical research, and cannabis based therapeutics related to neurological disorders. In addition to Turley and Mechoulam, speakers include:
- Orrin Devinsky, Professor of Neurology, Neurosurgery, and Psychiatry at the NYU School of Medicine. He directs the NYU Comprehensive Epilepsy Center and is working on cannabis based clinical studies
- Ethan Russo, MD, a board-certified neurologist, psychopharmacology researcher, and Medical Director of PHYTECS, a biotechnology company researching and developing innovative approaches targeting the human endocannabinoid system (“ECS”)
- Kevin McKernan, CSO of Courtagen Life Sciences, and the first research scientist to sequence the Cannabis sativa L. genome
Presenters from the fields of research, medical practice, therapeutic development and production are welcome to submit abstracts by February 26, 2016, for oral or poster presentations. Sponsorship opportunities are available as well. Keep up with news on Facebook https://www.facebook.com/cannmedevents, Twitter
http://www.twitter.com/CannMedEvents, and Instagram
Registration is currently open for attendees, with early-bird discounts available until February 15. For information, registration, and abstract submissions, please visit http://www.medicinalgenomics.com/CannMed2016/
About Gridiron Cannabis Coalition, LLC
Gridiron Cannabis Coalition is an organization dedicated to the advancement of medicinal cannabis as a treatment for brain disease and bodily injuries resulting from playing professional sports. Driven by research and development, GCC is committed to the evolution of the natural healing elements of the cannabis plant. Made up of current and former NFL players, cannabis industry experts, and medical professionals, GCC’s mission is to promote cannabis and other natural holistic medicines as an alternative to dangerous pharmaceuticals. For more information please visit www.gridironcannabis.com.
About Medicinal Genomics Corporation
Medicinal Genomics Corporation applies state-of-the-art life science technology to Cannabis plant genetics. Our products help growers, dispensaries, and safety testing laboratories characterize and understand the quality of medicinal cannabis. Medicinal Genomics utilizes a highly sophisticated Next Generation Sequencing laboratory, bioinformatics system, and DNA based technologies to deliver unmatched technical solutions to decipher the genetic code and quality level of medicinal Cannabis. Medicinal Genomics is a wholly owned subsidiary of Courtagen Life Sciences, Inc. For more information, please visit http://www.medicinalgenomics.com/.
About Courtagen Life Sciences, Inc.
Courtagen Life Sciences, Inc., located in Woburn, MA, is a CLIA/CAP certified molecular information company focused on the diagnosis of a range of neurological disorders. Courtagen operates a highly sophisticated Next Generation DNA Sequencing, bioinformatics, and clinical interpretation business. Courtagen’s work helps physicians elucidate the linkages between the genotypes and phenotypes of various neurological diseases. For more information, please visit http://www.courtagen.com/.
Mike Catalano, 877-395-7608